The market may remain range-bound, with support at the previous week’s low. Below are some short-term trading ideas to ...

Ozempic has been widely discussed internationally for its use among celebrities and its impact on weight loss; however, the ...

Cipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide ...

Global blockbuster fat-busting injection Mounjaro became India's top-selling medicine brand within months of its launch ...

The latest announcement is out from Cipla Ltd ( ($IN:CIPLA) ). Cipla Ltd has been assigned an Environmental, Social, and Governance (ESG) rating ...

Mumbai: The Bombay Natural History Society (BNHS) and the government's fisheries department conducted a workshop for ...

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...

Bank of Baroda, Mankind Pharma and Ashoka Buildcon will also be some of the other stocks to watch.

Track 10 key stocks including IndiGo, LIC, Cipla, and TCS for major news and market updates—see which companies are making ...

Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said, "The launch of Yurpeak marks a transformative moment in the fight against obesity and type 2diabetes ...

Yurpeak is the second tirzepatide brand from Eli Lilly to be launched in the country after receiving approval from the drug regulator.